Glaucoma therapy mode of actions compared

Article

Although both latanoprost and timolol-dorzolamide fixed combination (TDFC) decrease 24-hour intraocular pressure (IOP) and enhance diastolic ocular perfusion pressure (DOPP) in primary open-angle glaucoma (POAG) patients, their mechanisms of action are different, according to study results published online by Investigative Ophthalmology and Visual Science.

Although both latanoprost and timolol-dorzolamide fixed combination (TDFC) decrease 24-hour intraocular pressure (IOP) and enhance diastolic ocular perfusion pressure (DOPP) in primary open-angle glaucoma (POAG) patients, their mechanisms of action are different, according to study results published online by Investigative Ophthalmology and Visual Science.

Luciano Quaranta, of the Clinica Oculistica at the Università degli Studi Brescia, Italy and colleagues conducted a randomized trial on patients with untreated POAG (n=27), who received either TDFC twice daily followed by latanoprost once daily or latanoprost twice daily followed by TDFC once daily for a period of six weeks. The team measured systolic (SBP) and diastolic (DBP) blood pressure as well as IOP, and then conducted variance analysis to establish the relationship between treatment regimens and DOPP.

TDFC reduced 24-hour IOP to 15.4±1.9 mmHg; both SBP and DBP were also reduced by this treatment regimen. Latanoprost reduced IOP to 16.7±1.7 mmHg, although neither SBP nor DBP were decreased. Both treatments increased DOPP equally.

Thus the team concluded that TDFC enhanced DOPP by reducing IOP sufficiently to counteract the DBP decrease; although latanoprost caused a smaller reduction in IOP than TDFC, after latanprost treatment DBP remained stable and so DOPP was increased.

Newsletter

Get the essential updates shaping the future of pharma manufacturing and compliance—subscribe today to Pharmaceutical Technology and never miss a breakthrough.

Recent Videos
Omer Trivizki, MD, MBA, a retina specialist from Tel Aviv Medical Center, speaks about VOY-101, a Novel, Complement-Modulating Gene Therapy for Geographic Atrophy at the American Society of Retina Specialists (ASRS) Annual Meeting
João Pedro Marques, MD, MSc, PhD discusses a retrospective study of 800 patients with inherited retinal diseases during the American Society of Retina Specialists (ASRS) annual meeting
Christine Curcio, PhD, of the University of Alabama at Birmingham Heersink School of Medicine, shares histology update and revised nomenclature for OCT with Sheryl Stevenson of the Eye Care Network and Ophthalmology Times
© 2025 MJH Life Sciences

All rights reserved.